Johnson & Johnson’s one-dose COVID-19 vaccine is in its third phase of a clinical trial with 45,000 enrollees. The reported results so far are promising, and the potential impact game-changing. Senior Correspondent Brenda Flanagan explains why.
More from this episode
Views expressed by our advertisers and sponsors are their own, and are not endorsed by NJ Spotlight News.